1. Pre-Arrival Processes - Travellers Intending to enter Ghana
   a. All international passengers including those from the ECOWAS region, intending to fly to Ghana, will be required to be fully vaccinated.
   b. All International passengers including those from the ECOWAS region must complete a Port Health Declaration Form at https://www.ghs-hdf.org/hdf/ before embarkation of flight to Ghana.

2. Arriving Passengers - Travellers Entering Ghana
   Ghanaian and Foreign Residents
   a. 18 years and above arriving in Ghana will be required to provide evidence of full vaccination for a COVID-19 vaccine at the point of embarkation and upon arrival at Kotoka International Airport (KIA).
   b. Fully vaccinated will be exempted from pre-departure COVID-19 PCR testing from point of embarkation.
   c. Fully vaccinated will be exempted from COVID-19 testing upon arrival at the KIA.
   d. Partially vaccinated or unvaccinated will be required to present a NEGATIVE 48hrs PCR test result to the airline before embarkation and upon arrival.
   e. Partially vaccinated or unvaccinated will undergo COVID-19 testing at the KIA upon arrival.
   f. Partially vaccinated or unvaccinated will undergo COVID-19 vaccination at KIA upon arrival.

   Non-Ghanaians:
   a. At the point of embarkation must provide evidence of full vaccination status to the Airline prior to embarkation. (Airlines that board non-Ghanaians without evidence of full vaccination will be considered to have violated the COVID-19 guidelines for Ghana and shall be fined $5,500.00)
   b. Travelling to Kotoka International Airport with fake or forged vaccination certificates shall be quarantined and returned to the point of embarkation at their own cost.

   All Arriving passengers will undergo temperature screening, Yellow Fever Card verification and COVID-19 vaccination certificate verification as required.

3. Transit Passengers
   a. Passengers transiting and transferring through KIA will be required to be fully vaccinated and in addition adhere to COVID-19 testing requirements at the destination countries.

4. Exemptions
   a. Children under 18 years (Ghanaians and non-Ghanaians) who are unvaccinated are exempted from pre-departure COVID-19 PCR testing and COVID-19 testing upon arrival at the Airport in Ghana.
   b. Airline crew are exempted from the pre-departure and arrival COVID-19 testing and should follow the Airline policy for testing.
   c. Passengers who arrive under emergency circumstances such as diverted flights will not be required to undergo testing if they do not leave the airport or remain in isolation in their hotel.

5. Travelling with Pets
   a. Travelling with pets into Ghana is allowed in line with guidelines of the Veterinary Services Directorate of the Ministry of Food & Agriculture.

6. Departure Process - Passengers exiting Ghana
   a. Passengers departing Accra will be required to adhere to COVID-19 testing requirements for the destination countries.
   b. Departing passengers will undergo temperature screening at the entrance of Terminal 3 departures.

7. Wearing of Nose Mask
   a. Wearing of nose mask is mandatory in all Airport Terminals and ancillary buildings

8. Vaccination
   Definition of Fully Vaccinated - A person is said to be fully vaccinated when he/she has taken the full dose of vaccines approved and registered by the Food and Drugs Authority (FDA). Ghana or other vaccines prequalified by WHO (https://covid19.trackvaccines.org/agency/who) as in Table 1.
   All Passengers must present a valid COVID-19 vaccination certificate showing that they were fully vaccinated at least 14 days before embarkation except partially vaccinated or unvaccinated Ghanaians who are required to present a NEGATIVE 48hrs PCR test result to the airline before embarkation and to Port Health upon arrival.
# Updated COVID-19 Guidelines for Kotoka International Airport (KIA)

**Revision 15: Effective Date: 1st September, 2022 at 0000 Hours (UTC)**

<table>
<thead>
<tr>
<th>SN</th>
<th>Name of Vaccine</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sputnik V (Gam-COVID-Vac)</td>
<td>Gamaleya National Centre of Epidemiology and Microbiology, Russia</td>
</tr>
<tr>
<td>2</td>
<td>Covishield® (Oxford/AstraZeneca formulation)</td>
<td>Serum Institute of India (SIPL) India</td>
</tr>
<tr>
<td>4</td>
<td>Pfizer – BioNTech’s Comirnaty (BNT162b2)</td>
<td>BioNTech Manufacturing GmbH, Kupferbergerringasse 17-19, 55116 Mainz, Germany. Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium</td>
</tr>
<tr>
<td>5</td>
<td>Moderna’s Spikevax (mRNA-1273)</td>
<td>Roovi Pharma Industrial Services, S.A, San Sebastian de los Reyes, Paseo de Europa, 50, 28070, Madrid, Spain</td>
</tr>
<tr>
<td>6</td>
<td>Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (AZD1222)</td>
<td>AstraZeneca AB (Sweden)</td>
</tr>
</tbody>
</table>

**Others Granted Emergency Use Listing (EUL) by WHO**

<table>
<thead>
<tr>
<th>SN</th>
<th>Name of Vaccine</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Covaxin</td>
<td>Bharat Biotech, India</td>
</tr>
<tr>
<td>8</td>
<td>BBIBP-COV</td>
<td>Sinopharm (Beijing) China</td>
</tr>
<tr>
<td>9</td>
<td>Coronavac</td>
<td>SinoVac, China</td>
</tr>
<tr>
<td>10</td>
<td>COVAX/VX COVID-19 vaccine (SARS-CoV-2 rS Protein Nanoparticle (Recombinant))</td>
<td>Serum Institute of India Pvt. Ltd.</td>
</tr>
<tr>
<td>11</td>
<td>NUMAXVID™ COVID-19 vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted])</td>
<td>Novavax CZ a.s.</td>
</tr>
</tbody>
</table>

**Additional Information and Guides can be accessed on the Ghana Health Service and Africa CDC website**

---

**For further information, please contact GACL Contact Centre on:** 0302-556012